Journal of Nephrology

, Volume 32, Issue 1, pp 75–81 | Cite as

Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease

  • Valentina Rovella
  • Michele Ferrannini
  • Manfredi Tesauro
  • Giulia Marrone
  • Andrea Busca
  • Roberto Sorge
  • Simone Manca di Villahermosa
  • Maurizio Casasco
  • Nicola Di DanieleEmail author
  • Annalisa NoceEmail author
Original Article


Background and aim

The synthetic drug fenoldopam mesylate (FM) may have a renoprotective role, and a “renal dose” of 0.1 µg/kg/min intravenous (IV) infusion of FM has been reported as able to increase renal blood flow without affecting systemic blood pressure. But conclusive data are still lacking. We aimed to investigate by color-Doppler ultrasonography the effects of IV administration of FM at this dosage in hypertensive chronic kidney disease (CKD) patients, and verify whether it may induce any systemic hemodynamic alteration.


In 60 hypertensive CKD patients, we measured by duplex Doppler ultrasonography, at baseline and during infusion of 0.1 µg/kg/min of FM, the systolic and diastolic flow velocity (sampled at the renal hilum, intermediate section and origin of both renal arteries) and the intra-parenchymal renal resistive index (RRI) sampled on interlobular arteries of both kidneys. Patients were divided into four subgroups (I–IV) according to classification of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-DOQI).


Infusion of 0.1 µg/kg/min FM significantly decreased the RRI (0.73 ± 0.05 vs. 0.65 ± 0.06; p < 0.0001) and increased the systolic and diastolic flow velocities in all renal artery tracts examined. No single episode of systemic hypotension was observed.


Very low-dose FM may significantly increase renal blood flow and exert a renal protective effect in hypertensive CKD patients. Infusion of FM at such low dosage appears also to be quite safe, even in CKD and hypertensive patients.


Fenoldopam mesylate Chronic kidney disease Renal resistive index Arterial hypertension Renal blood flow 


Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Number EudraCT: 2010-019523-63.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Taylor AA, Shepherd AM, Polvino W, Mangoo-Karim R, Ballard K, Sunthornyothin S, Luther RR, Pool JL (1999) Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. Am J Hypertens 12(9 Pt 1):906–914CrossRefGoogle Scholar
  2. 2.
    Ziemniak JA, Boppana VK, Cyronak MJ, Stote RM (1989) A retrospective analysis of fenoldopam renal excretion in 65 subjects: evidence for possible intrarenal formation of fenoldopam from its metabolites. Pharm Res 6(8):702–705CrossRefGoogle Scholar
  3. 3.
    Weber RR, McCoy CE, Ziemniak JA, Frederickson ED, Goldberg LI, Murphy MB (1988) Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. Br J Clin Pharmacol 25(1):17–21CrossRefGoogle Scholar
  4. 4.
    Goldberg LI (1984) Dopamine receptors and hypertension. Physiologic and pharmacologic implications. Am J Med 77(4A):37–44CrossRefGoogle Scholar
  5. 5.
    Meco M, Cirri S (2010) Effects of fenoldopam mesylate on central hemodynamics and renal flow in patients undergoing cardiac surgery: color Doppler echocardiographic evaluation. J Cardiothorac Vasc Anesth 24(1):58–62. CrossRefGoogle Scholar
  6. 6.
    Kien ND, Moore PG, Jaffe RS (1992) Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs. Anesth Analg 74(1):72–78CrossRefGoogle Scholar
  7. 7.
    Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63(5):713–735. CrossRefGoogle Scholar
  8. 8.
    Li G, Xu J, Wang P, Velazquez H, Li Y, Wu Y, Desir GV (2008) Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation 117(10):1277–1282. CrossRefGoogle Scholar
  9. 9.
    Gill RW (1985) Measurement of blood flow by ultrasound: accuracy and sources of error. Ultrasound Med Biol 11(4):625–641CrossRefGoogle Scholar
  10. 10.
    Stavros AT, Parker SH, Yakes WF, Chantelois AE, Burke BJ, Meyers PR, Schenck JJ (1992) Segmental stenosis of the renal artery: pattern recognition of tardus and parvus abnormalities with duplex sonography. Radiology 184(2):487–492. CrossRefGoogle Scholar
  11. 11.
    Pastore A, De Angelis S, Casciani S, Ruggia R, Di Giovamberardino G, Noce A, Splendiani G, Cortese C, Federici G, Dessi M (2006) Effects of folic acid before and after vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with known MTHFR genotypes. Clin Chem 52(1):145–148. CrossRefGoogle Scholar
  12. 12.
    Lohman TG, Roche AF, Martorell R (1988) Anthropometric standardization reference manual. Human Kinetics Books, ChampaignGoogle Scholar
  13. 13.
    Dessi M, Noce A, Agnoli A, De Angelis S, Fuiano L, Tozzo C, Taccone-Gallucci M, Fuiano G, Federici G (2009) The usefulness of the prognostic inflammatory and nutritional index (PINI) in a haemodialysis population. Nutr Metab Cardiovasc Dis 19(11):811–815. CrossRefGoogle Scholar
  14. 14.
    Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J (2010) Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 55(4):648–659. CrossRefGoogle Scholar
  15. 15.
    Meco M, Cirri S (2010) The effect of various fenoldopam doses on renal perfusion in patients undergoing cardiac surgery. Ann Thorac Surg 89(2):497–503. CrossRefGoogle Scholar
  16. 16.
    Mathur VS, Swan SK, Lambrecht LJ, Anjum S, Fellmann J, McGuire D, Epstein M, Luther RR (1999) The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 27(9):1832–1837CrossRefGoogle Scholar
  17. 17.
    Kim SH, Kim WH, Choi BI, Kim CW (1992) Duplex Doppler US in patients with medical renal disease: resistive index vs. serum creatinine level. Clin Radiol 45(2):85–87CrossRefGoogle Scholar
  18. 18.
    Hanamura K, Tojo A, Kinugasa S, Asaba K, Fujita T (2012) The resistive index is a marker of renal function, pathology, prognosis, and responsiveness to steroid therapy in chronic kidney disease patients. Int J Nephrol 2012:139565. CrossRefGoogle Scholar
  19. 19.
    Radermacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel MJ, Galanski M, Koch KM, Haller H (2001) Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 344(6):410–417. CrossRefGoogle Scholar
  20. 20.
    Lerolle N, Guerot E, Faisy C, Bornstain C, Diehl JL, Fagon JY (2006) Renal failure in septic shock: predictive value of Doppler-based renal arterial resistive index. Intensive Care Med 32(10):1553–1559. CrossRefGoogle Scholar
  21. 21.
    Schnell D, Deruddre S, Harrois A, Pottecher J, Cosson C, Adoui N, Benhamou D, Vicaut E, Azoulay E, Duranteau J (2012) Renal resistive index better predicts the occurrence of acute kidney injury than cystatin C. Shock 38(6):592–597. CrossRefGoogle Scholar
  22. 22.
    Parolini C, Noce A, Staffolani E, Giarrizzo GF, Costanzi S, Splendiani G (2009) Renal resistive index and long-term outcome in chronic nephropathies. Radiology 252(3):888–896. CrossRefGoogle Scholar
  23. 23.
    Darmon M, Schortgen F, Vargas F, Liazydi A, Schlemmer B, Brun-Buisson C, Brochard L (2011) Diagnostic accuracy of Doppler renal resistive index for reversibility of acute kidney injury in critically ill patients. Intensive Care Med 37(1):68–76. CrossRefGoogle Scholar
  24. 24.
    Marik PE, Varon J (2009) Perioperative hypertension: a review of current and emerging therapeutic agents. J Clin Anesth 21(3):220–229. CrossRefGoogle Scholar
  25. 25.
    Della Rocca G, Pompei L, Costa MG, Coccia C, Scudeller L, Di Marco P, Monaco S, Pietropaoli P (2004) Fenoldopam mesylate and renal function in patients undergoing liver transplantation: a randomized, controlled pilot trial. Anesth Analg 99(6):1604–1609. table of contents.CrossRefGoogle Scholar
  26. 26.
    Naeem M, McEnteggart GE, Murphy TP, Prince E, Ahn S, Soares G (2015) Fenoldopam for the prevention of contrast-induced nephropathy (CIN)-do we need more trials? A meta-analysis. Clin Imaging 39(5):759–764. CrossRefGoogle Scholar
  27. 27.
    Gillies MA, Kakar V, Parker RJ, Honore PM, Ostermann M (2015) Fenoldopam to prevent acute kidney injury after major surgery-a systematic review and meta-analysis. Crit Care 19:449. CrossRefGoogle Scholar
  28. 28.
    Sehgal CM, Arger PH, Silver AC, Patton JA, Saunders HM, Bhattacharyya A, Bell CP (2001) Renal blood flow changes induced with endothelin-1 and fenoldopam mesylate at quantitative Doppler US: initial results in a canine study. Radiology 219(2):419–426. CrossRefGoogle Scholar
  29. 29.
    Radermacher J (2002) Ultrasonogragraphy in the diagnosis of renovascular disease. Imaging Decis 6(2):15–22CrossRefGoogle Scholar
  30. 30.
    Hunter DW, Chamsuddin A, Bjarnason H, Kowalik K (2001) Preventing contrast-induced nephropathy with fenoldopam. Tech Vasc Interv Radiol 4(1):53–56CrossRefGoogle Scholar

Copyright information

© Italian Society of Nephrology 2018

Authors and Affiliations

  • Valentina Rovella
    • 1
  • Michele Ferrannini
    • 1
  • Manfredi Tesauro
    • 1
  • Giulia Marrone
    • 1
    • 2
  • Andrea Busca
    • 1
  • Roberto Sorge
    • 3
  • Simone Manca di Villahermosa
    • 1
  • Maurizio Casasco
    • 4
  • Nicola Di Daniele
    • 1
    Email author
  • Annalisa Noce
    • 1
    Email author
  1. 1.Division of Hypertension and Nephrology, Department of Systems MedicineUniversity of Rome “Tor Vergata”RomeItaly
  2. 2.PhD School of Applied Medical-Surgical SciencesUniversity of Rome “Tor Vergata”RomeItaly
  3. 3.Laboratory of Biometry, Department of Systems MedicineUniversity of Rome “Tor Vergata”RomeItaly
  4. 4.Federazione Medico Sportiva ItalianaRomeItaly

Personalised recommendations